Thanks...Off to the doctor...see you later...🥳
Recent LIMN News
- Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody • GlobeNewswire Inc. • 03/17/2026 12:08:00 PM
- Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 02/17/2026 01:44:00 PM
- Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation • GlobeNewswire Inc. • 10/30/2025 02:04:29 PM
- Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative • GlobeNewswire Inc. • 07/28/2025 11:30:00 AM
- Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies • GlobeNewswire Inc. • 07/25/2025 12:31:58 PM
- Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy • GlobeNewswire Inc. • 07/24/2025 12:31:00 PM
- Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy • GlobeNewswire Inc. • 07/22/2025 05:30:00 PM
